Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.
Actively Recruiting
Researchers are evaluating surgical options for patients with low risk differentiated thyroid cancer. This phase III study aims to determine if hemithyroidectomy, which removes part of the thyroid gland, is an acceptable and cost-effective alternative to total thyroidectomy, which removes the entire gland. The trial includes two groups of patients based on their prior surgery status and diagnosis method, focusing on recurrence risk and prognosis. Participants are randomly assigned to different surgical treatments depending on their group. Group 1 patients who have had prior thyroid surgery will either have a second operation to remove the remaining thyroid tissue or undergo surveillance without further surgery. Group 2 patients who have not had surgery will be randomized to receive either hemithyroidectomy or total thyroidectomy in a single operation. The trial plans to recruit 456 participants and follow them regularly for six years after surgery. During the study, patients will attend follow-up visits post-surgery and then annually for six years. Researchers will monitor cancer recurrence rates at three and five years, assess the site and risk of recurrence, and record additional investigations and procedures after surgery. They will also evaluate surgical complications, voice function, hormone replacement needs, quality of life, and healthcare resource use at multiple time points. This comprehensive monitoring aims to compare outcomes between the different surgical approaches and understand their impact on patients health and well-being over time.
Actively Recruiting
Researchers are evaluating whether regular MRI scans can better detect progression in patients on active surveillance for low to medium risk prostate cancer compared to the current standard care defined by NICE. The study aims to see if MRI scans reduce the number of PSA tests, biopsies, and clinic visits over five years while improving cancer progression detection. This trial involves patients who have chosen active surveillance and have a histological diagnosis of localized prostate cancer. Participants are randomly assigned to one of two groups. The standard care group will have PSA tests every 3 months in the first year, then every 6 months with annual rectal exams when clinically indicated, and an MRI at 12 months if not done at diagnosis. Biopsies occur if PSA or rectal exams indicate changes. The intervention group will have PSA tests every 6 months and regular MRI scans annually for patients with visible lesions or medium risk cancer, or in years 1, 3, and 5 for others. Targeted biopsies are performed if MRI PRECISE scores are 4 or higher. The MRI scans are biparametric and do not use gadolinium contrast. Participants will be followed for five years with regular PSA tests, MRI scans, biopsies when indicated, and clinical assessments. Researchers will monitor biopsy and staging results, cost-effectiveness, adverse events related to MRI and biopsies, treatment decisions, compliance, and quality of life using questionnaires on prostate symptoms, anxiety, and general health. The trial is not blinded and aims to provide evidence to improve active surveillance protocols while reducing invasive procedures and healthcare costs.
Actively Recruiting
Researchers are evaluating treatment options for patients with localized renal cell carcinoma RCC who have undergone nephrectomy and are at intermediate or high risk of disease recurrence. This phase III randomized controlled platform trial, called RAMPART, aims to assess whether durvalumab alone or combined with tremelimumab can improve disease-free survival or overall survival compared to the current standard care of active monitoring. The study includes patients with Leibovich scores between 3 and 11, focusing on those at intermediate and high risk of relapse after surgery. Participants will be randomly assigned to one of three groups active monitoring for one year, durvalumab monotherapy given as 1500 mg infusions every four weeks for up to 13 cycles, or a combination of durvalumab same dosing with tremelimumab administered twice during the first month. The trial monitors patients over several years to compare outcomes between these groups, including disease-free survival, overall survival, and metastasis-free survival. During the study, participants will undergo clinical and radiological assessments, including post-operative CT scans before randomization and routine follow-ups during treatment and observation. Researchers will collect tissue samples and blood for future research. Safety and health will be closely monitored through laboratory tests, ECGs, and performance status evaluations. The study may last up to 20 years for the longest follow-up on overall survival and other outcomes.
Actively Recruiting
Researchers are conducting a Phase III clinical trial to evaluate the effects and safety of pumitamig in patients with triple-negative breast cancer TNBC who have locally recurrent inoperable or metastatic disease and are ineligible for PDL1 therapy due to PD-L1 negative status. This trial compares pumitamig combined with chemotherapy to placebo combined with chemotherapy, using a randomized, double-blind design to measure progression-free survival and overall survival. Participants will be randomly assigned to one of two groups one receiving pumitamig plus a physicians choice of chemotherapy and the other receiving a placebo plus the same chemotherapy options. Chemotherapy regimens include paclitaxelnab-paclitaxel, gemcitabine plus carboplatin, or eribulin, administered by standard intravenous infusion. The treatment continues until disease progression, intolerable side effects, withdrawal, death, or trial end. After treatment, participants enter a safety follow-up period for up to 90 days and a survival follow-up phase lasting until death, withdrawal, loss of contact, or sponsor decision. During the study, participants undergo screening lasting up to 28 days before treatment begins. Assessments include tumor measurement using RECIST criteria, tissue sample collection excluding certain biopsy types, and performance status evaluation. Researchers track multiple outcome measures such as tumor response rates, quality of life scores, adverse events, and survival rates over periods up to approximately 49 months. This comprehensive monitoring ensures participant safety and collects data on the trial drugs impact compared to placebo with chemotherapy.
Actively Recruiting
Heart failure with preserved ejection fraction HFpEF occurs when the hearts pumping function is normal but the heart cannot pump blood properly. This condition causes symptoms like breathlessness, swollen feet and ankles, and tiredness. HFpEF is complex and varies widely among patients, making it poorly understood with limited treatment options. The UK HFpEF study aims to improve understanding of why people develop HFpEF, create better diagnostic tests, identify new treatments, and follow participants health over many years. This observational study involves creating a large registry by collaborating across many centers in the UK. The registry will collect detailed information from thousands of patients with HFpEF, enabling researchers to classify the condition more precisely and develop personalized treatment approaches. This platform will support future research trials targeting specific patient groups and enable efficient patient recruitment. Participants will undergo detailed assessments including clinical evaluations, measurements of natriuretic peptide levels, and long-term health monitoring. Researchers will analyze data to identify distinct HFpEF subgroups, understand causes, and improve risk prediction over a 10-year period. This study is designed to provide important insights for better care and treatment strategies, with ongoing follow-up to track health outcomes.